308 related articles for article (PubMed ID: 2522912)
1. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells.
Chang WC; Fujimiya Y; Casteel N; Pattengale P
Int J Cancer; 1989 Apr; 43(4):591-7. PubMed ID: 2522912
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
3. Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia. I. Analysis of the defect using the monoclonal antibodies HNK-1 (LEU-7) and B73.1.
Fujimiya Y; Bakke A; Chang WC; Linker-Israeli M; Udis B; Horwitz D; Pattengale PK
Int J Cancer; 1986 May; 37(5):639-49. PubMed ID: 3457769
[TBL] [Abstract][Full Text] [Related]
4. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
[TBL] [Abstract][Full Text] [Related]
5. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission.
Dabholkar M; Tatake R; Amin K; Advani S; Gangal S
Oncology; 1989; 46(2):123-7. PubMed ID: 2785254
[TBL] [Abstract][Full Text] [Related]
6. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
7. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
Verfaillie C; Miller W; Kay N; McGlave P
Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
[TBL] [Abstract][Full Text] [Related]
8. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
9. NK cell function in severe combined immunodeficiency (SCID): evidence of a common T and NK cell defect in some but not all SCID patients.
Peter HH; Friedrich W; Dopfer R; Müller W; Kortmann C; Pichler WJ; Heinz F; Rieger CH
J Immunol; 1983 Nov; 131(5):2332-9. PubMed ID: 6415162
[TBL] [Abstract][Full Text] [Related]
10. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
[TBL] [Abstract][Full Text] [Related]
11. Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases.
Morimoto C; Romain PL; Fox DA; Anderson P; DiMaggio M; Levine H; Schlossman SF
Am J Med; 1988 May; 84(5):817-25. PubMed ID: 2966579
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 production and response by helper T-cell subsets in man.
Salmon M; Kitas GD; Gaston JS; Bacon PA
Immunology; 1988 Sep; 65(1):81-5. PubMed ID: 2972603
[TBL] [Abstract][Full Text] [Related]
13. Patients with abnormal proportions of T-lymphocyte subsets have reduced in vitro cellular immunity.
Chudwin DS; Cowan MJ; Wara DW; Ammann AJ
Clin Immunol Immunopathol; 1983 Jan; 26(1):126-36. PubMed ID: 6223739
[TBL] [Abstract][Full Text] [Related]
14. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells in chronic leukemia. Function and markers.
Sørskaar D; Førre O; Stavem P
Int Arch Allergy Appl Immunol; 1988; 87(2):159-64. PubMed ID: 2973442
[TBL] [Abstract][Full Text] [Related]
16. Natural killer and natural killer-like cell activity of peripheral blood and intrathyroidal mononuclear cells from patients with Graves' disease.
Tezuka H; Eguchi K; Fukuda T; Otsubo T; Kawabe Y; Ueki Y; Matsunaga M; Shimomura C; Nakao H; Ishikawa N
J Clin Endocrinol Metab; 1988 Apr; 66(4):702-7. PubMed ID: 3257969
[TBL] [Abstract][Full Text] [Related]
17. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
[TBL] [Abstract][Full Text] [Related]
18. Natural killer (NK)-cell activity in sorted subsets of peripheral blood mononuclear cells from patients with severe combined immunodeficiency.
ten Berge RJ; Schellekens PT; Budding-Koppenol A; Dooren LJ; Vossen JM
J Clin Immunol; 1987 May; 7(3):198-202. PubMed ID: 3597714
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.
Damle NK; Doyle LV; Bradley EC
J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965
[TBL] [Abstract][Full Text] [Related]
20. Production of interleukin-2 (IL-2) and expression of IL-2 receptor in patients with IgA nephropathy.
Lee TW; Kim MJ
Korean J Intern Med; 1992 Jan; 7(1):31-8. PubMed ID: 1477028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
